# Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy

> **NCT00793975** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 37 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** IMC-1121B
- **BIOLOGICAL:** 1121B
- **BIOLOGICAL:** 1121B
- **BIOLOGICAL:** 1121B
- **BIOLOGICAL:** 1121B
- **BIOLOGICAL:** 1121B
- **BIOLOGICAL:** 1121B

## Key facts

- **NCT ID:** NCT00793975
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2013-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00793975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00793975, "Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00793975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*